Diagnosing muscular dystrophy typically involves a combination of blood tests, genetic testing, and clinical evaluation, often starting after a parent or doctor notices unusual muscle weakness in a child. The process can take anywhere from a few months to over a year depending on the type of muscular dystrophy, with Duchenne muscular dystrophy (DMD) patients historically facing a median 12-month delay from first symptoms to confirmed diagnosis. Here’s what each step looks like and why it matters.
Early Physical Signs That Prompt Testing
The diagnostic process usually begins when a child shows signs of proximal muscle weakness, meaning weakness in the muscles closest to the center of the body like the hips, thighs, and shoulders. One of the most recognizable indicators is the Gowers sign: a child who has to “climb up” their own thighs with their hands in order to stand from the floor. Before the full Gowers maneuver develops, subtler signs appear, including mild hand pressure against the thigh while rising, a wide-based gait, and walking on the toes.
A telling feature is the tendency to roll into a prone (face-down) position before standing up, which persists beyond age 3. Children may also develop an exaggerated curve in the lower back and sway their hips noticeably while walking, both compensations for weakened gluteal muscles. Another physical clue is the “valley sign,” where the muscles around the shoulder blade appear uneven because some are enlarged while others have wasted away. A doctor performing a physical exam will also ask about family history of muscular dystrophy and document the specific pattern of weakness, since different types affect different muscle groups.
Blood Tests: Creatine Kinase as a First Screen
The simplest and fastest initial test is a blood draw measuring creatine kinase (CK), an enzyme that leaks out of damaged muscle cells. Normal CK levels fall between roughly 35 and 232 U/L. In Duchenne muscular dystrophy, CK is dramatically elevated from birth, often 10 to 100 times the normal range. That means a child with DMD might show CK levels in the thousands or even tens of thousands.
A very high CK level doesn’t confirm muscular dystrophy on its own, since inflammatory muscle diseases like polymyositis can also raise CK to similar levels. But it’s a strong signal that something is damaging muscle tissue and that further testing is needed. Other blood markers like aldolase and lactate dehydrogenase may also be checked, though CK is the most sensitive for muscle damage.
Genetic Testing: The Definitive Answer
Genetic testing is now the gold standard for confirming a diagnosis and identifying the specific type of muscular dystrophy. For DMD and Becker muscular dystrophy, testing focuses on the dystrophin gene, which is the largest gene in the human body with 79 coding segments (exons).
The most common first-line genetic test is called MLPA (multiplex ligation-dependent probe amplification). This test identifies deletions or duplications of one or more exons, which account for about 70% of all DMD mutations. It’s the most cost-effective starting point because it catches the majority of cases in a single step. An alternative method called array CGH uses probes covering both the coding and non-coding regions of the gene, offering broader coverage.
If MLPA comes back normal, about 20% of patients will have smaller mutations within individual exons that require a different approach. These are found through sequencing of each exon individually, which is more labor-intensive and expensive. Newer next-generation sequencing techniques can detect deletions, duplications, and small mutations all in one test, and these are increasingly replacing the stepwise approach.
For limb-girdle muscular dystrophies, which include more than 20 genetic subtypes, doctors narrow down which genes to test based on the patient’s specific pattern of weakness. Clinical guidelines from the American Academy of Neurology provide detailed flowcharts to help neurologists match symptoms to the most likely genetic culprits, making testing more efficient.
Muscle Biopsy: When Genetics Aren’t Enough
A muscle biopsy involves removing a small piece of muscle tissue, either through a needle or a small incision, and examining it under a microscope. While genetic testing has reduced the need for biopsies, they remain valuable when genetic results are inconclusive or when doctors need to see exactly what’s happening at the protein level.
For suspected DMD, the biopsy is stained to detect dystrophin, the protein that the dystrophin gene produces. In healthy muscle, dystrophin lines the membrane of every muscle fiber. In DMD, dystrophin is essentially absent: western blot testing shows levels at 0 to 5% of normal, while immunostaining (which visualizes the protein directly in tissue) shows 5 to 20% of normal. The discrepancy between these two methods is a known challenge, and they don’t always correlate with each other. Different antibodies used in the staining process can yield results that vary by as much as threefold.
Beyond dystrophin levels, the biopsy reveals characteristic patterns of damage. Muscular dystrophy tissue shows widespread variation in muscle fiber size, with some fibers abnormally enlarged and others shrunken. Fibrosis, where muscle is replaced by scar tissue, appears in 56% of dystrophy biopsies compared to only 10% in inflammatory muscle diseases. These features help distinguish dystrophy from conditions that can look similar on blood tests and clinical exams.
EMG and Nerve Studies
Electromyography (EMG) measures the electrical activity of muscles by inserting thin needle electrodes into the tissue. Its primary role in the diagnostic process is distinguishing between muscle diseases (myopathies) and nerve diseases (neurogenic disorders), which can sometimes look similar from the outside.
In muscular dystrophy, EMG typically shows a “myopathic” pattern: motor unit action potentials are shorter in duration and lower in amplitude than normal, and the muscle recruits more motor units earlier than it should to compensate for weak fibers. Some forms of muscular dystrophy also produce spontaneous electrical activity, including fibrillation potentials and positive sharp waves, which indicate active muscle fiber damage. This spontaneous activity can overlap with what’s seen in inflammatory myopathies, which is why EMG alone isn’t diagnostic. However, certain patterns like complex repetitive discharges are more common in inflammatory conditions (found in 70% of juvenile polymyositis cases versus 22% of dystrophy cases), providing another piece of the puzzle.
MRI: Mapping Muscle Damage
Muscle MRI has become an increasingly useful tool that serves two purposes. First, it identifies which muscles are most affected and which are relatively spared, creating a pattern that can point toward specific genetic subtypes. Different forms of muscular dystrophy attack different muscles in characteristic ways. For example, one subtype might preferentially damage the muscles at the back of the thigh while sparing those in front, while another shows the opposite pattern.
Second, MRI helps guide muscle biopsies by identifying muscles that are actively affected but not yet completely replaced by fat, which yields the most informative tissue samples. In advanced disease stages, some muscles may be entirely replaced by fatty tissue, making them poor biopsy targets. Imaging both the thigh and calf is recommended, since one region may be more informative than the other depending on disease progression.
How Muscular Dystrophy Is Distinguished From Similar Conditions
Several conditions mimic muscular dystrophy closely enough to cause diagnostic confusion, particularly inflammatory myopathies like polymyositis. Both cause proximal weakness and elevated CK levels. The key differentiators are muscle atrophy (present in 89% of dystrophy patients versus 46% of those with inflammatory myopathy), the presence of myositis-specific autoantibodies (found in 54% of inflammatory myopathy patients but zero dystrophy patients), and biopsy findings like fibrosis and fiber hypertrophy that are much more common in dystrophy.
Response to treatment also provides a clue, though it comes later in the process. About 44% of patients with juvenile polymyositis have a complete response to immunosuppressive treatment, while no dystrophy patients respond to these medications. MRI of the thighs also helps: muscle atrophy visible on imaging was present in 83% of dystrophy patients versus 19% of those with inflammatory myopathy.
Newborn Screening: A Recent Development
In December 2025, HHS Secretary Robert F. Kennedy Jr. approved adding Duchenne muscular dystrophy to the Recommended Uniform Screening Panel (RUSP), the federal list of conditions recommended for universal newborn screening. This is a significant shift in how DMD may be caught in the future, potentially identifying affected boys at birth rather than waiting for symptoms to appear around ages 2 to 5.
States individually decide whether to adopt RUSP recommendations, so implementation will vary. But if widely adopted, newborn screening could dramatically shorten the diagnostic timeline and allow families to begin supportive care and monitoring from the earliest possible stage.
Heart and Lung Monitoring After Diagnosis
Once muscular dystrophy is confirmed, the diagnostic workup doesn’t stop at the muscles. Many forms of muscular dystrophy affect the heart, so an electrocardiogram (to check heart rhythm) and echocardiogram (to check heart structure and pumping strength) are standard parts of the evaluation. Pulmonary function testing measures breathing capacity, which declines as the muscles involved in respiration weaken. These baseline measurements become reference points for tracking disease progression over time.